Xeltis has secured nearly €50 million in financing to advance the commercialization of its groundbreaking blood vessel implant, aXess, following promising clinical trial results.

Information on the Target

Xeltis, a pioneering medtech company, is at the forefront of developing transformative implants that facilitate the natural creation of living and durable blood vessels. The company aims to revolutionize the treatment options available to millions who require hemodialysis access grafts or cardiovascular replacements each year. Their flagship product, aXess, is an innovative blood vessel designed specifically for hemodialysis vascular access and is currently undergoing clinical development.

Founded in the Netherlands, Xeltis is leveraging its proprietary Endogenous Tissue Restoration (ETR) technology to create advanced polymer implants that not only regenerate patients' own tissues but also leave behind long-lasting vessels as the implant is absorbed. The company is backed by a robust array of investors, including EQT Life Sciences and Invest-NL, ensuring a solid financial foundation for future growth.

Industry Overview in the Target’s Specific Country

The medtech industry in the Netherlands is recognized as one of the most advanced sectors within Europe, characterized by strong governmental support, leading-edge research institutions, and a favorable regulatory environment. This industry is vital to the nation’s ec